Anupama Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anupama Singh has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Emanuele Mazzola
Department of Data Science, Dana-Farber Cancer Institute, Boston, USA
9 shared publicationsMichael T. Jaklitsch
Division of Thoracic and Cardiac Surgery, Brigham and Women’s Hospital, Boston, USA
9 shared publicationsMiles McAllister
7 shared publicationsYue Xie
Department of Data Science, Dana-Farber Cancer Institute, Boston, USA
6 shared publicationsAshley L. Deeb
5 shared publicationsFatemehsadat Pezeshkian
Division of Thoracic and Cardiac Surgery, Brigham and Women’s Hospital, Boston, USA
5 shared publications
Latest Publications
- 31 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5427
ASO Visual Abstract: Multifactorial Impact of Age, Race and Female Sex on Management of Non-small Cell Lung Cancer
- 31 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5427
ASO Visual Abstract: Multifactorial Impact of Age, Race and Female Sex on Management of Non-small Cell Lung Cancer
- 14 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5410-5418
Multifactorial Impact of Age, Race, and Female Sex on Management of Non-small Cell Lung Cancer
The purpose of this study was to evaluate the impact of age and race on female patients with non-small cell lung cancer (NSCLC) and identify factors posing
- 14 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5410-5418
Multifactorial Impact of Age, Race, and Female Sex on Management of Non-small Cell Lung Cancer
The purpose of this study was to evaluate the impact of age and race on female patients with non-small cell lung cancer (NSCLC) and identify factors posing
- Open Access
- 1 September 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (9) , 6451-6460
Survival of patients with node-negative lung cancer and chest wall invasion
Background: Patients with T3 non-small cell lung cancer (NSCLC) with chest wall invasion (CWI) have poorer survival than patients with T3 NSCLC defined by other T3 descriptors, but their survival has not been compared with patients with T4 NSCLC. Our objective was to compare the survival of patients with NSCLC with CWI, currently a T3 descriptor, with that of patients with T4 NSCLC. Methods: A retrospective analysis was conducted of the National Cancer Database (NCDB) comparing patients diagnosed with node-negative NSCLC Results: In total, 1,734 matched patients were studied (867 T3 with CWI, 867 T4). There were no significant differences in baseline demographics, tumor characteristics, treatment, or surgical approach used (all P>0.05). There were no significant differences in 30-day (P=0.27) or 90-day (P=0.33) mortality between the two groups. Five-year OS was also similar between the two groups [44.0% T3 with CWI, 95% confidence interval (CI): 41–47% vs. 43.8% T4, 95% CI: 40–47%; P=0.50]. Median survival was 40 months (range 0.2–123 months for the T3 cohort and 0.3–120 months for the T4 cohort). Conclusions: CWI might serve better as a T4 descriptor in future iterations of the Tumor, Node, Metastasis (TNM) classifications. This would allow providers to better stage and treat patients, which would subsequently affect survival.
- 1 September 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (9) , 6451-6460
Open AccessSurvival of patients with node-negative lung cancer and chest wall invasion
Background: Patients with T3 non-small cell lung cancer (NSCLC) with chest wall invasion (CWI) have poorer survival than patients with T3 NSCLC defined by other T3 descriptors, but their survival has not been compared with patients with T4 NSCLC. Our objective was to compare the survival of patients with NSCLC with CWI, currently a T3 descriptor, with that of patients with T4 NSCLC. Methods: A retrospective analysis was conducted of the National Cancer Database (NCDB) comparing patients diagnosed with node-negative NSCLC Results: In total, 1,734 matched patients were studied (867 T3 with CWI, 867 T4). There were no significant differences in baseline demographics, tumor characteristics, treatment, or surgical approach used (all P>0.05). There were no significant differences in 30-day (P=0.27) or 90-day (P=0.33) mortality between the two groups. Five-year OS was also similar between the two groups [44.0% T3 with CWI, 95% confidence interval (CI): 41–47% vs. 43.8% T4, 95% CI: 40–47%; P=0.50]. Median survival was 40 months (range 0.2–123 months for the T3 cohort and 0.3–120 months for the T4 cohort). Conclusions: CWI might serve better as a T4 descriptor in future iterations of the Tumor, Node, Metastasis (TNM) classifications. This would allow providers to better stage and treat patients, which would subsequently affect survival.
- 3 May 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (7) , 4709-4710
ASO Visual Abstract: Gait Speed as a Measure of Frailty and Outcomes After Lung Resection
- 3 May 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (7) , 4709-4710
ASO Visual Abstract: Gait Speed as a Measure of Frailty and Outcomes After Lung Resection
- 27 February 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4181-4188
Gait Speed as a Measure of Frailty and Outcomes After Lung Resection
As a powerful, objective marker of frailty, 4-m gait speed (4MGS) can predict morbidity and mortality in various populations including cardiac surgery and
- 27 February 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4181-4188
Gait Speed as a Measure of Frailty and Outcomes After Lung Resection
As a powerful, objective marker of frailty, 4-m gait speed (4MGS) can predict morbidity and mortality in various populations including cardiac surgery and
- Open Access
Optimizing Care Across the Continuum for Older Adults with Lung Cancer: A Review
Older adults with lung cancer experience inferior clinical outcomes compared to their younger counterparts. This review provides the scaffolding to address these disparities by delineating (1) the distinct and varied care needs of older adults with lung malignancies, (2) evidence-based measures for identifying subgroups within this population meriting tailored approaches to care, (3) age-specific considerations for the selection of cancer-directed therapy, and (4) opportunities for future work to enhance clinical outcomes and care delivery.
Open AccessOptimizing Care Across the Continuum for Older Adults with Lung Cancer: A Review
Older adults with lung cancer experience inferior clinical outcomes compared to their younger counterparts. This review provides the scaffolding to address these disparities by delineating (1) the distinct and varied care needs of older adults with lung malignancies, (2) evidence-based measures for identifying subgroups within this population meriting tailored approaches to care, (3) age-specific considerations for the selection of cancer-directed therapy, and (4) opportunities for future work to enhance clinical outcomes and care delivery.
- Open Access
- 1 September 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (9) , 5615-5623
Early thoracic surgery consultation and location of therapy impact time to esophagectomy
Background: Neoadjuvant chemoradiation therapy (nCRT) followed by esophagectomy is the standard treatment for resectable, locally advanced esophageal cancer. The ideal timing between neoadjuvant therapy and esophagectomy is unclear. Delayed esophagectomy is associated with worse outcomes. We investigated which factors impacted time to esophagectomy in our patients. Methods: We conducted a retrospective analysis of prospectively collected data of patients with pT0-3N0-2 esophageal cancers who underwent CROSS trimodality therapy from May 2016 to January 2020. Sociodemographic factors, comorbidities, and neoadjuvant factors (location of CRT, treatment toxicity, discontinuation of treatment) were compared between patients who underwent surgery within 60 days and those after 60 days. Results: In total, 197 patients were analyzed of whom 137 underwent esophagectomy within 60 days (early surgery, ES) and 60 were outside that window (delayed surgery, DS). More DS patients had a history of myocardial infarction (MI) or stroke (both 11.67% vs. 3.65%, P=0.05) and required CRT dose reduction (16.67% vs. 6.57%, P=0.04). Fewer DS patients received CRT at Dana-Farber Cancer Institute (DFCI) or a DFCI satellite site (33.33% vs. 58.4%, P=0.01) and saw our surgeons before CRT completion (68.33% vs. 89.78%, P=0.001). CRT at DFCI [odds ratio (OR) 2.63, P=0.01] or a satellite site (OR 3.07, P=0.01) and evaluation by a thoracic surgeon (OR 4.07, P=0.001) shortened time to esophagectomy. History of MI (OR 0.29, P=0.04), stroke (OR 0.29, P=0.04), and CRT dose reduction (OR 0.35, P=0.03) delayed time to esophagectomy. Conclusions: Improving access to multispecialty cancer centers and increasing satellite sites may improve time to esophagectomy.
- 1 September 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (9) , 5615-5623
Open AccessEarly thoracic surgery consultation and location of therapy impact time to esophagectomy
Background: Neoadjuvant chemoradiation therapy (nCRT) followed by esophagectomy is the standard treatment for resectable, locally advanced esophageal cancer. The ideal timing between neoadjuvant therapy and esophagectomy is unclear. Delayed esophagectomy is associated with worse outcomes. We investigated which factors impacted time to esophagectomy in our patients. Methods: We conducted a retrospective analysis of prospectively collected data of patients with pT0-3N0-2 esophageal cancers who underwent CROSS trimodality therapy from May 2016 to January 2020. Sociodemographic factors, comorbidities, and neoadjuvant factors (location of CRT, treatment toxicity, discontinuation of treatment) were compared between patients who underwent surgery within 60 days and those after 60 days. Results: In total, 197 patients were analyzed of whom 137 underwent esophagectomy within 60 days (early surgery, ES) and 60 were outside that window (delayed surgery, DS). More DS patients had a history of myocardial infarction (MI) or stroke (both 11.67% vs. 3.65%, P=0.05) and required CRT dose reduction (16.67% vs. 6.57%, P=0.04). Fewer DS patients received CRT at Dana-Farber Cancer Institute (DFCI) or a DFCI satellite site (33.33% vs. 58.4%, P=0.01) and saw our surgeons before CRT completion (68.33% vs. 89.78%, P=0.001). CRT at DFCI [odds ratio (OR) 2.63, P=0.01] or a satellite site (OR 3.07, P=0.01) and evaluation by a thoracic surgeon (OR 4.07, P=0.001) shortened time to esophagectomy. History of MI (OR 0.29, P=0.04), stroke (OR 0.29, P=0.04), and CRT dose reduction (OR 0.35, P=0.03) delayed time to esophagectomy. Conclusions: Improving access to multispecialty cancer centers and increasing satellite sites may improve time to esophagectomy.
- Open Access
- 17 July 2024
- Published by Elsevier in Surgery Open Science
- Vol. 20, 189-193
Early adoption of robotic lung resection in an established video assisted thoracic surgery practice
- 17 July 2024
- Published by Elsevier in Surgery Open Science
- Vol. 20, 189-193
Open AccessEarly adoption of robotic lung resection in an established video assisted thoracic surgery practice
- Open Access
- 22 March 2024
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (3) , 535-539
Secondary Esophageal Cancer After Hematopoietic Stem Cell Transplant: An Institutional Case Series
- 22 March 2024
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (3) , 535-539
Open AccessSecondary Esophageal Cancer After Hematopoietic Stem Cell Transplant: An Institutional Case Series
- 1 March 2024
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (3)
Complete anatomic segmentectomy shows improved oncologic outcomes compared to incomplete anatomic segmentectomy
To compare oncologic outcomes after segmentectomy with division of segmental bronchus, artery, and vein (complete anatomic segmentectomy) versus segmentectomy with division of < 3 segmental structures (incomplete anatomic segmentectomy). We conducted a single-center, retrospective analysis of patients undergoing segmentectomy from 03/2005-05/2020. Operative reports were audited to classify procedures as complete or incomplete anatomic segmentectomy. Patients who underwent neoadjuvant therapy or pulmonary resection beyond indicated segments were excluded. Survival was estimated with Kaplan-Meier models and compared using log-rank tests. Cox proportional hazards models were used to estimate hazard ratios for death. Cumulative incidence functions for locoregional recurrence were compared with Gray’s test, with death considered a competing event. Cox and Fine-Gray models were used to estimate cause-specific and subdistribution hazard ratios, respectively, for locoregional recurrence. Of 390 cases, 266 (68.2%) were complete and 124 were incomplete anatomic segmentectomy. Demographics, pulmonary function, tumor size, stage, and perioperative outcomes did not significantly differ between groups. Surgical margins were negative in all but one case. Complete anatomic segmentectomy was associated with improved lymph node dissection (5 vs. 2 median nodes sampled; p<0.001). Multivariable analysis revealed reduced incidence of locoregional recurrence (CSHR=0.42; 95% CI 0.22-0.80; SDHR=0.43; 95% CI 0.23-0.81), and non-significant improvement in overall survival (HR = 0.66; 95% CI: 0.43-1.00) after complete vs. incomplete anatomic segmentectomy. This single-center experience suggests complete anatomic segmentectomy provides superior locoregional control and may improve survival relative to incomplete anatomic segmentectomy. We recommend surgeons perform complete anatomic segmentectomy and lymph node dissection whenever possible.
- 1 March 2024
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (3)
Complete anatomic segmentectomy shows improved oncologic outcomes compared to incomplete anatomic segmentectomy
To compare oncologic outcomes after segmentectomy with division of segmental bronchus, artery, and vein (complete anatomic segmentectomy) versus segmentectomy with division of < 3 segmental structures (incomplete anatomic segmentectomy). We conducted a single-center, retrospective analysis of patients undergoing segmentectomy from 03/2005-05/2020. Operative reports were audited to classify procedures as complete or incomplete anatomic segmentectomy. Patients who underwent neoadjuvant therapy or pulmonary resection beyond indicated segments were excluded. Survival was estimated with Kaplan-Meier models and compared using log-rank tests. Cox proportional hazards models were used to estimate hazard ratios for death. Cumulative incidence functions for locoregional recurrence were compared with Gray’s test, with death considered a competing event. Cox and Fine-Gray models were used to estimate cause-specific and subdistribution hazard ratios, respectively, for locoregional recurrence. Of 390 cases, 266 (68.2%) were complete and 124 were incomplete anatomic segmentectomy. Demographics, pulmonary function, tumor size, stage, and perioperative outcomes did not significantly differ between groups. Surgical margins were negative in all but one case. Complete anatomic segmentectomy was associated with improved lymph node dissection (5 vs. 2 median nodes sampled; p<0.001). Multivariable analysis revealed reduced incidence of locoregional recurrence (CSHR=0.42; 95% CI 0.22-0.80; SDHR=0.43; 95% CI 0.23-0.81), and non-significant improvement in overall survival (HR = 0.66; 95% CI: 0.43-1.00) after complete vs. incomplete anatomic segmentectomy. This single-center experience suggests complete anatomic segmentectomy provides superior locoregional control and may improve survival relative to incomplete anatomic segmentectomy. We recommend surgeons perform complete anatomic segmentectomy and lymph node dissection whenever possible.